Cheaper diabetes drug gets OKWASHINGTON — Federal health officials have approved a cheaper version of the world’s top-selling insulin from Sanofi for millions of U.S. patients with diabetes.The Food and Drug Administration approved a new form of Sanofi’s pen-like injector, Lantus, from drugmakers Eli Lilly and Boehringer Ingelheim.Those companies received tentative FDA approval for their drug, called Basaglar, in August 2014. But the launch was delayed by a patent dispute with Sanofi. The three drugmakers reached an agreement in September allowing the launch of the new drug.Insulin is a hormone that is crucial for controlling sugar levels in the blood. People with diabetes either do not produce enough insulin or cannot properly use it.Lantus is the top product for Sanofi and the third best-selling medicine in the world by revenue. British research firm GlobalData says Lantus had sales of $12.4 billion in 2014.

Meadows track, casino soldHOUSTON, Pa. — An eastern Pennsylvania spinoff company of Penn National Gaming is buying The Meadows Racetrack & Casino for $440 million.The sale price is $25 million less than Gaming & Leisure Properties of Wyomissing offered in May 2014. Gaming & Leisure sued Cannery Casino Resorts, which owned The Meadows, claiming the company overstated the casino’s financial performance, which was the basis of the sale price.The reduced price settles that litigation and saves the sale.